RedHill Biopharma Ltd. (RDHL)

NASDAQ: RDHL · IEX Real-Time Price · USD
0.820
+0.052 (6.72%)
At close: Jun 24, 2022 4:00 PM
0.810
-0.010 (-1.220%)
After-hours: Jun 24, 2022 7:58 PM EDT
6.72%
Market Cap 43.67M
Revenue (ttm) 83.42M
Net Income (ttm) -92.02M
Shares Out 53.26M
EPS (ttm) -2.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 17,154,047
Open 0.860
Previous Close 0.768
Day's Range 0.762 - 0.876
52-Week Range 0.620 - 11.180
Beta 1.93
Analysts Buy
Price Target 13.26 (+1,517.1%)
Earnings Date Jun 23, 2022

About RDHL

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infectio... [Read more...]

Industry Pharmaceuticals
Founded 2009
CEO Dror Ben-Asher
Employees 201
Stock Exchange NASDAQ
Ticker Symbol RDHL
Full Company Profile

Financial Performance

In 2021, RDHL's revenue was $85.76 million, an increase of 33.25% compared to the previous year's $64.36 million. Losses were -$97.74 million, 28.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for RDHL stock is "Buy." The 12-month stock price forecast is 13.26, which is an increase of 1,517.07% from the latest price.

Price Target
$13.26
(1,517.07% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Hot Penny Stocks to Buy Right Now? Check These 3 Out

Can these penny stocks make gains this coming week? The post Hot Penny Stocks to Buy Right Now?

Other symbols: CMRXJAGX

RedHill Biopharma Shares Trading Higher On Improved Q1 Profitability

RedHill Biopharma Ltd (NASDAQ: RDHL) plans announced a cost reduction plan expected to generate operational cost savings of approximately $50 million over the next 18 months. Most of these savings resul...

RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22

Targeting positive cash from operations to start during H2/22 [1] Focus on earlier achievement of operational profitability thanks to a recently implemented comprehensive cost reduction plan, with expec...

RedHill Biopharma to Host First Quarter 2022 Financial Results and Operational Highlights Webcast on June 23, 2022

TEL AVIV, Israel and RALEIGH, N.C. , June 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd.

RedHill Presents New Talicia® Data Analyses at DDW 2022

Talicia's efficacy and safety profile evaluated in patients with H. pylori infection and diabetes mellitus, a large and challenging patient population associated with sub-optimal outcomes with clarithro...

RedHill Biopharma Announces $15 Million Registered Direct Offering with a Leading Healthcare Investor

TEL AVIV, Israel and RALEIGH, N.C , May 9, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has ent...

Redhill Biopharma Ltd. (RDHL) Could Find Support Soon, Here's Why You Should Buy the Stock Now

Redhill Biopharma Ltd. (RDHL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart.

RedHill Biopharma Says Opaganib Can Potentially Work Against COVID-19 Omicron Subvariants

RedHill Biopharma Ltd's (NASDAQ: RDHL) opaganib (ABC294640), an oral drug candidate for hospitalized COVID-19 patients, demonstrated potent in vitro efficacy against the omicron variant while maintainin...

RedHill Reports Potent Inhibition of Omicron with Oral COVID-19 Drug Candidate Opaganib In Vitro

- Oral opaganib's reported potent in vitro activity against Omicron adds to previously observed inhibition of Delta and other SARS-CoV-2 variants of concern that cause COVID-19; Testing conducted by The...

RedHill Biopharma Ltd Announces Potent Omicron Inhibition with RedHill's Opaganib

Oral opaganib's reported potent in vitro activity against Omicron adds to previously observed inhibition of Delta and other SARS-CoV-2 variants of concern that cause COVID-19; Testing conducted by The U...

RedHill Biopharma Reports Operational Highlights and Fourth Quarter & Full Year 2021 Financial Results

TEL AVIV, Israel and RALEIGH, N.C., March 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd.

RedHill, Kukbo Ink Oral Opaganib Licensing Pact For COVID-19 In South Korea

RedHill Biopharma Ltd (NASDAQ: RDHL) has entered into an exclusive license agreement with Kukbo Co Ltd for oral opaganib to treat COVID-19 in South Korea.  Under the terms of the license agreement, whic...

RedHill and Kukbo Enter Oral Opaganib License for COVID-19 in South Korea

TEL-AVIV, Israel, and RALEIGH, N.C. , March 15, 2022 /PRNewswire/ -- RedHill Biopharma Ltd.

RedHill Biopharma to Host Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights Webcast on M...

TEL AVIV, Israel and RALEIGH, NC , March 10, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will ...

RedHill Announces Positive Phase 2 Study Results with Oral RHB-107 in Non-Hospitalized COVID-19

TEL AVIV, Israel and RALEIGH, N.C., March 1, 2022 /PRNewswire/ --  RedHill Biopharma Ltd.

RedHill Biopharma Announces Record Quarterly Revenues and First Commercial Operations Breakeven

TEL AVIV, Israel and RALEIGH, N.C., Feb. 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd.

RedHill Biopharma's Oral Opaganib Reduces Mortality by 70% Given on Top of Remdesivir and Corticosteroids in Severe C...

TEL AVIV, Israel and RALEIGH, N.C.  , Feb. 7, 2022 /PRNewswire/ -- RedHill Biopharma Ltd.

RedHill Biopharma's Oral COVID-19 Treatment Improves Median Time To Viral RNA Clearance

RedHill Biopharma Ltd (NASDAQ: RDHL) announced new data from a prespecified analysis of all oral opaganib's Phase 2/3 study patients in COVID-19 patients. The data demonstrated that opaganib improved th...

3 Top Penny Stocks To Watch As Redditors Buy The Dip

Popular penny stocks on Reddit today. Are they a buy?

Other symbols: RETOSBEV

RedHill Biopharma's Oral Opaganib Significantly Improves Viral Clearance in Phase 2/3 Study in Severely Ill Hospitali...

- In a prespecified analysis of all Phase 2/3 study patients with positive PCR at screening, opaganib improved the median time to viral RNA clearance by at least 4 days; Median of 10 days for viral clea...

RedHill Biopharma and Gaelan Medical Enter Into License Agreement for Talicia® for the United Arab Emirates

RALEIGH, N.C. and TEL-AVIV, Israel, Jan. 6, 2022 /PRNewswire/ --  RedHill Biopharma Ltd.

RedHill Announces Additional Insider Buying

RALEIGH, NC and TEL-AVIV, ISRAEL / ACCESSWIRE / December 15, 2021 / RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that members...

RedHill Biopharma Announces Additional Insider Buying

RALEIGH, N.C. and TEL-AVIV, Israel, Dec. 15, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.

RedHill Biopharma's Talicia Recommended For H. Pylori Infection

RedHill Biopharma Ltd (NASDAQ: RDHL) has announced the publication of a new study revealing concerning rates of widespread, physician-directed prescribing of clarithromycin-based regimens for H. pylori ...

RedHill Biopharma Ltd Announces Concerning Clarithromycin Rx Rates for H. pylori

RedHill Biopharma: Concerning Rates of Clarithromycin Prescribing for H. pylori, Despite Increasing Antibiotic Resistance, Uncovered in New Digestive Diseases & Sciences Publication Despite increasing r...